Table 1 |
||||||||||
|
Characteristics of the study subjects. |
||||||||||
| EU code |
Year of birth |
Sex |
IDU started |
Risk ended |
Serology |
Enrollment |
Follow-up ended |
|||
|
|
||||||||||
| HBc |
HBs |
HCV |
HTLV |
Year |
Year |
|||||
|
|
||||||||||
| W276 |
1960 |
M |
1979 |
2003 |
+ |
- |
+ |
+ |
1996 |
2004 |
| W278 |
1955 |
M |
1978 |
2000 |
- |
- |
+ |
+ |
1996 |
2004 |
| W336 |
1958 |
M |
1975 |
2001 |
+ |
- |
+ |
+ |
1996 |
2004 |
| B184 |
1951 |
M |
1972 |
2003 |
+ |
- |
+ |
+ |
1998 |
2004 |
| B195 |
1949 |
F |
1972 |
Unknown |
+ |
- |
+ |
- |
1998 |
1999 |
|
|
||||||||||
|
HBc: anti-hepatitis B virus antibodies; HBs: hepatitis B antigen; HCV: hepatitis C virus; HTLV: human T cell leukaemia/lymphoma virus (I and/or II) |
||||||||||
|
Sáez-Cirión et al. Retrovirology 2006 3:81 doi:10.1186/1742-4690-3-81 |
||||||||||
